Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in shares of Genelux Co. (NASDAQ:GNLX) by 36.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 63,800 shares of the company’s stock after selling 36,600 shares during the period. Renaissance Technologies LLC’s holdings in Genelux were worth $124,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Woodward Diversified Capital LLC increased its holdings in shares of Genelux by 0.3% in the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after buying an additional 3,687 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Genelux by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock worth $6,578,000 after acquiring an additional 24,220 shares during the last quarter. AMG National Trust Bank raised its position in shares of Genelux by 49.7% during the second quarter. AMG National Trust Bank now owns 75,351 shares of the company’s stock worth $147,000 after purchasing an additional 25,000 shares during the period. LifeSteps Financial Inc. lifted its holdings in shares of Genelux by 50.2% during the second quarter. LifeSteps Financial Inc. now owns 66,536 shares of the company’s stock valued at $130,000 after purchasing an additional 22,227 shares during the last quarter. Finally, Miracle Mile Advisors LLC acquired a new position in shares of Genelux in the 2nd quarter valued at $58,000. 37.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GNLX has been the topic of several recent analyst reports. Roth Capital upgraded Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm began coverage on shares of Genelux in a report on Tuesday, August 27th. They set a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.33.

Insider Buying and Selling at Genelux

In other news, major shareholder Aladar Szalay sold 40,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $2.29, for a total value of $91,600.00. Following the transaction, the insider now directly owns 1,099,821 shares of the company’s stock, valued at approximately $2,518,590.09. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 331,062 shares of company stock valued at $736,831 in the last quarter. Company insiders own 9.30% of the company’s stock.

Genelux Trading Down 0.4 %

Shares of Genelux stock opened at $2.61 on Monday. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $22.27. The stock has a 50-day moving average price of $2.27 and a 200 day moving average price of $2.81. The company has a market cap of $89.66 million, a P/E ratio of -2.69 and a beta of -1.54.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, equities analysts forecast that Genelux Co. will post -0.9 earnings per share for the current fiscal year.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.